1 / 2

Intravenous Immunoglobulin (IVIG) Market Expected to Reach $15,964 Million by 2025

Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to antigens, which are foreign to the host system.

Shrikantchavan725
Download Presentation

Intravenous Immunoglobulin (IVIG) Market Expected to Reach $15,964 Million by 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Intravenous Immunoglobulin Market According to a new report published by Allied Market Research, titled, "Intravenous Immunoglobulin (IVIG) Market by Application and Type: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"the global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/325?utm_source=pdf&utm_medium=N iranjan Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds its application in various fields, including hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, & hypogammaglobulinemia; increase in immunoglobulin indications; improved production & purification processes; growth in awareness toward antibody deficiency; and rare immune disorders among patient population drive the growth of the global intravenous immunoglobulin market. Based on application segment, hypogammaglobulinemia held the largest market share in 2017, and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment. Purchase Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/325?utm_source=pdf&utm_medium =Niranjan Key Findings of the Intravenous Immunoglobulin (IVIG) Market: Myasthenia gravis segment is projected to grow at the highest rate during the forecast period. • Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period. • North America dominated the global intravenous immunoglobulin market in 2017. • LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025. •

  2. In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities. The key companies profiled in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer AG. The other players included in the value chain analysis (but not included in the report) are Omrix Biopharmaceuticals Ltd.; Behring GmbH; Shanghai RAAS Blood Products Co., Ltd.; Option Care Enterprises, Inc.; ADMA Biologics, Inc.; and BioScrip, Inc.

More Related